Marinus Pharmaceuticals, Inc. to Present at the 21st Annual

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marinus Pharmaceuticals, Inc. to Present at the 21st Annual BioCentury Newsmakers Conference on Friday, September 26, 2014

NEW HAVEN, Conn., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS ), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Edward F. Smith, Vice President and Chief Financial Officer of Marinus will present at the 21 st Annual BioCentury Newsmakers Conference on Friday, September 26, 2014 at 3:00 p.m. (EDT) at the Millennium Broadway Hotel and Conference Center in New York.

The Company's presentation will be available via a live webcast. To access the live audio webcast, please logon through the link located in the Investors section of the Marinus website at www.marinuspharma.com under the Events & Presentations tab. 

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors. For additional information, please visit the Company's website at www.marinuspharma.com .

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include, among others, statements regarding our expectations regarding our development plans for our product candidate, including optimizing a product's formulation and the clinical trial testing schedule. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical trials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters, including the development of formulations of ganaxolone, that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

Edward F. Smith Vice President, CFO, Secretary and Treasurer Marinus Pharmaceuticals, Inc. (215) 437-0610

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 87

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 84

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 170

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 84

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 128

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 98

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 64

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 94

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading